-
Education, Training, & Certifications
-
-
Selected Grants
-
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, and Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years
awarded by Teva Branded Pharmaceutical Products R&D, Inc
2022 - 2027
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe
awarded by Teva Branded Pharmaceutical Products R&D, Inc
2022 - 2027
-
A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment
of Chronic Migraine in Pedia
awarded by Teva Branded Pharmaceutical Products R&D, Inc
2022 - 2027
-
A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive
awarded by Noema Pharma
2022 - 2024
-
Preventing Epilepsy Using Vigabatrin in Infants With Tuberous Sclerosis Complex (PREVeNT Trial)
awarded by University of Alabama at Birmingham
2018 - 2021
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.
